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In clinical research, there has been an in-
creasing need to titrate ethical, legal and 
insurance requirements to the type of 
study, so that higher-risk research receives 
necessary and appropriate detailed atten-
tion, while low-risk studies can proceed 
more rapidly.
Spontaneous Medically Advantageous 
Research Trials (SMART) are non-profit 
studies that carry minimal or no risk to pa-
tients. This type of investigation, however, 
is currently hampered by the fact that, in 
many hospitals and jurisdictions it has 
to undergo the same bureaucratic proce-
dures and safety assessments as high-risk, 
for-profit studies. We strongly believe that 
such practice of scientific research assess-
ment should be radically modified. We 
advocate a new, specific research category 
for SMART investigations that grants 
them a preferential route from conception 
to ethics assessment to execution. In addi-
tion, we argue that such low risk studies 
assessing common, often not evidence-
based applied treatments or investigations 
should in fact be a mandatory component 
of modern medicine. All clinicians, scien-
tists, patients, patient associations, politi-
cians, scientific associations and common 
citizens should be involved in this process, 
as they all play a crucial role in its evolu-
tion and success.
We contend that modern medical research 
and entire health systems should transi-
tion to a novel model of healthcare system 
where SMART execution is embedded into 
daily practice, in order to minimize anec-
dotal practice and maximize evidence-
based practice.
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“It is not the strongest or the most intel-
ligent who will survive but those who can 
best manage change.” Charles Darwin
We contend that, in 2015, the Helsinki 
Declaration and Ethical Committees are, at 
times, indirectly disadvantaging patients. 
In this article we try to explain the reasons 
why and the possible solutions.
One of the objectives of modern health 
care is to create a learning health care 
system. The Institute of Medicine defines 
such a health care system as one “in which 
knowledge generation is so embedded into 
the core of the practice of medicine that it 
is a natural outgrowth and product of the 
healthcare delivery process and leads to 
continual improvement in care”. (1)
Research and clinical practice, however, 
have historically been clearly two distinct 
areas of medical science: by contrast, the 
learning health system emphasizes the 
fundamental need to integrate these two 
aspects of healthcare into one whole. (2)
The model of the learning health care sys-
tem is, of course, in line with the corner-
stone of human research ethics, the 1964 
Declaration of Helsinki, (3) and its revi-
sions and clarifications.
This concept encompasses a set of ethical 
principles regulating human experimen-
tation developed by the World Medical 
Association. The fundamental principles 
are the respect for the single patient, the 
right to self-determination and the right 
to make informed decisions regarding 
participation in research, both initially 
and during the course of the study. While 
there is a continuous need for research and 
improvement, the subject’s welfare must 
always come before the interest of science, 
and ethical considerations must precede 
and guide laws and regulations. The in-
vestigator’s primary concern must be the 
safety and well-being of the subject or vol-
unteer.
Faden et al. recently proposed a Common 
Purpose Framework (4) aimed at promot-
ing the implementation of the model of a 
modern health care system into clinical 
reality. This framework is built on the tra-
ditional principles of clinical and research 
ethics, but at the same time the system is 
also conceived to guide activities where re-
search and practice are integrated to enable 
rapid, systematic, and effective learning.
The proposed Common Purpose Frame-
work comprises seven moral precepts (4): 
a) respect the rights and dignity of pa-
tients; b) respect the clinical judgments of 
clinicians; c) provide optimal care to each 
patient d) avoid imposing nonclinical risks 
and burdens on patients; e) reduce health 
inequalities among populations; f) conduct 
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activities that foster learning from clinical 
care and clinical information; g) contribute 
to the common purpose of improving the 
quality and value of clinical care and health 
care systems.
The first six obligations directly involve 
researchers, clinicians, health care admin-
istrators, institutions, and insurers. The 
seventh, on the contrary, invites patients to 
participate in some learning activities that 
are integrated in their clinical care.
In such a health care system, transparency 
to patients is obviously crucial. However, in 
this sense, for example, patients might not 
be routinely informed about each learning 
activity, provided that these are seen not 
to carry risks for patients that are greater 
than the risks associated with standard. On 
the contrary, patients would always be in-
formed, and their consent would always be 
sought, whenever a learning activity might 
impact on the quality of care or its out-
comes. (4) This concept is extraordinarily 
modern and challenging, but still far from 
being a clinical reality.
Despite this strong theoretical basis, the 
evolution of contemporary health care into 
a learning health care system is just begin-
ning, and many different health care sys-
tems in different countries are organized 
and regulated in their own way.
We truly believe that, in light of the pre-
ventable harm, waste, and uncertainty that 
affect clinical effectiveness in health care, 
all efforts to enhance and accelerate learn-
ing are extremely important. The first step 
towards implementing such a learning 
health system is to define its core ethics 
and its specific moral obligations.
Some ethical issues are crucial and yet 
extremely debated. The local Ethics Com-
mittee’s decision might sometimes con-
tradict national laws, but the power of 
Ethics Committees on the development 
of clinical trials has never been formally 
challenged. There has not been and there 
is no evidence-based assessment of their 
performance, the reproducibility of their 
judgments, and their accuracy in making 
such judgements.
A major issue in this regard is, for exam-
ple, whether informed consent should be 
always and indiscriminately required. We 
are fully aware of the pivotal importance of 
informed consent, but we believe it should 
not be indiscriminately applied especially 
where interventions or measurement are 
part of common or routine care.
Faden et al. further analyzed this aspect in 
a recent article published in the New Eng-
land Journal of Medicine (5) specifically 
addressing the role of informed consent in 
comparative effectiveness research (CER) 
studies. The authors emphasize that some 
randomized CER studies may proceed 
with a streamlined consent process and 
others may even not require patient con-
sent.
While we are fully aware that the current 
regulations on this matter are partially 
justified by past episodes of lack of obser-
vance of patients’ rights, we also believe 
that we have evolved and now face new, 
even opposite challenges: regulations and 
ethical requirements of research must keep 
up to date, or modern research will be ad-
versely affected, improvements in care will 
be delayed and patients will be ill-served.
We argue that current consent and over-
sight practices too often overprotect pa-
tients from research that has little direct 
effect on what is relevant for them and yet 
may lead to improved care over time. By 
doing so, in addition, they may deprive 
them and their next of kin and future pa-
tients of better care.
The recent “Regulation (EU) No 536/2014 
of the European Parliament and of the 
Council of 16 April 2014” addresses this 
issue, together with many other critical 
aspects of modern scientific research, but 
many problems remain and still warrant 
clarification. (6)
From our point of view, the power of local 
ethical committees may even have detri-
mental effects: by delaying and impeding 
SMART studies they may indirectly ad-
versely affect patient outcomes. In many 
jurisdictions, impediments, discussions, 
delays and costs due to local ethical com-
mittees are progressively worsening. 
Therefore, an unambiguous legislation is-
sued by a centralized referral institution is 
strongly recommended.
Another hot topic is non-profit research, 
which is a major driving force of medical 
progress. If non-profit studies are inde-
pendent from the influence of pharmaceu-
tical companies, they are in fact conceived 
and performed in the interest of patients, 
and lead to improvements in patient care.
In spite of this, approval of such studies 
is increasingly difficult all over the world. 
The bureaucratic and safety assessments 
they have to undergo are the same as those 
of pharmaceutical and for-profit studies, 
even when they are evaluating and com-
paring, for example, drugs that have been 
used in clinical practice for years and are 
prescribed according to non-evidence 
based physician preference or minimal dif-
ferences in drug doses. In our opinion, be-
wilderingly, sometimes local ethics com-
mittees and the need for informed consent 
impede this type of study often more than 
with pharmaceutical drug trials.
Sponsored pharmaceutical studies are of-
ten characterized by a relatively high risk/
great benefit dichotomy for patients, and 
their expenses for insurance, ethics com-
mittee and monitoring are generally fully 
covered by the commercial sponsor itself. 
Conversely, spontaneous non-profit stud-
ies, even when they put patients at negli-
gible risk (no greater on any estimate than 
the risk associated with being exposed to 
standard care), often undergo the same 
insurance, and bureaucratic requirements 
as sponsored studies, but without finan-
cial backing by a sponsor. This is another 
major limitation to the development of 
non-profit studies. The requirements of 
the ethical committee vary greatly from 
country to country across the continents. 
Some national realities show a very mod-
ern attitude toward research, but on the 
contrary in some contexts the ethical ap-
proval process strongly jeopardizes re-
search due to the prolonged time required 
(up to months) for the approval of the 
studies. For example, continuous require-
ments of further specifications and infor-
mation regarding the study are asked of the 
researchers because most of the members 
of the ethical committees are not medical 
doctors dealing with patients.
Furthermore, in our experience, many lo-
cal ethics committee evaluations require 
the payment of a fee (the amount is gen-
erally hundreds of Euros), and specific in-
surance has to be taken out even for non-
profit no-risk studies (thousands of Euros). 
Excessive monitoring and the need for 
dedicated personnel to follow the bureau-
cratic procedures with the ethics commit-
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tees, cause further considerable expenses. 
Financial resources are not enough and 
grants are limited in number and budget. 
The resulting time delay is impressive. 
Obstacles and requirements paradoxically 
increase when an initially single-centre, 
not-for-profit study aims at involving oth-
er centres, even though multicentre studies 
are those that provide the strongest scien-
tific evidence.
Today, with the entire world potentially 
connected and synchronized, it would be 
possible and relatively easy to perform in-
numerable trials on many every-day as-
pects of clinical practice, refining small de-
tails that, all together, would incrementally 
improve patient care as a whole. The direct 
impact on patient outcome and indirect re-
duction of medical expenses would likely 
be immensely beneficial to both patients 
and society on a global scale.
Based on these observations, we have 
developed a new concept of non-profit, 
negligible risk research. We identify the 
above-mentioned studies with the acro-
nym SMART, which stands for “Spontane-
ous, Medically Advantageous for patients 
Research Trials (SMART)”. The character-
istics of SMART studies are summarized 
in table 1. The term SMART includes any 
study that carries negligible risks for pa-
tients, does not study new drugs or devices 
and is not in the interest of pharmaceutical 
companies. At the same time, the informa-
tion that might be delivered by these stud-
ies is fundamentally important for the pa-
tient community worldwide.
Table 1. Profile of the Spontaneous Medically Advantageous Research Trials (SMART) concept. 
Characteristics Description
Nature of the study Non profit, spontaneous.
They offer the best consensus-established available standard treatment.
Risk for patients No additional risk (only those arising from standard clinical practice)
Benefits for patients Significant
Benefits for society Significant
Benefit for future patients Significant
Need for informed consent According to the study
Information provided Relevant
Ethics Committee expenses None
Insurance None (only the one already offered for standard clinical procedures)
Monitoring expenses None (simple, clinically relevant endpoints that could be obtained by 
standard electronic databases)
Ethical requirements Written approval from at least 10 independent physicians with at least 
20 papers already recently published in indexed journals and work-
ing in at least 10 different nations in at least 3 different continents. 
Final approval by a Central Ethical Committee only. 
Visibility Uploaded on an international on-line database
We would also like to stress the importance 
of the Hawthorne effect, which plays a rele-
vant role in these kind of studies. (7-11) The 
Hawthorne effect (also referred to as the ob-
server effect) is the phenomenon whereby 
individuals improve or modify an aspect of 
their behavior in response to the awareness 
of being observed. The original “Hawthorne 
effect” study suggested that the novelty of 
being research subjects and the increased 
attention from such could lead to tempo-
rary increases in workers’ productivity. 
Translated into the context of current scien-
tific research, this means that the simple fact 
of being research subjects and the increased 
attention from such, may improve patients’ 
outcome. The positive influence that clini-
cal trials may have on hospital survival was 
also directly posited by us in a recently pub-
lished editorial. (12) In this work we tried to 
identify the factors contributing to the ex-
tremely low perioperative mortality (0.3%) 
observed at our Institution when compared 
to published European standards.
All researchers strongly agree that evalua-
tion by an ethics committee, with or with-
out the need for written informed consent, 
should be mandatory for high risk studies, 
for those related to pharmaceutical com-
panies and to new drugs or devices, but 
lower costs and less bureaucracy might be 
considered appropriate for SMART type-
investigations.
The ethics and bureaucratic requirements 
and costs should be completely reshaped 
for SMART’s, allowing a bigger number of 
institutions and colleagues to share their 
data with the scientific community.
Our aim is to promote the evolution of the 
Health care system into a Learning health 
care system. We think that publicizing the 
concept of SMART research is a crucial 
step towards this objective.
We challenge the one-size-fits-all approach 
in clinical research bureaucracy in favour 
of a tailored approach, based on the effec-
tive likely risk to which each patient is ex-
posed due to his or her participation in the 
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study. We are aware that it would be unad-
visable and unethical for patients to pay a 
fee for access to research trials. At the same 
time, inclusion in a SMART study should 
often be considered a privilege and not an 
added risk, and both national and local 
health systems should support centers per-
forming SMART type studies rather than 
centers that do not undertake such studies.
Such a strategy would open new revolu-
tionary and challenging horizons in clini-
cal research. Furthermore, this new ap-
proach to research would not be limited 
to a specific sector, as it is by definition 
multi- and inter-disciplinary, and can be 
applied to all aspects of modern biomedi-
cal research. Revolutionizing current sci-
entific research practice is key to facing 
the above-mentioned problems of modern 
scientific research. Examples of studies 
which may be considered SMART include: 
observational (non-interventional) proto-
cols, either retrospective or prospective, 
audits, improvements in clinical practice 
studies, before-and-after studies of prac-
tice changes, spontaneous randomized 
and cluster cross-over randomized trials of 
widely used and currently widely applied 
therapies.
These studies provide crucial information 
for scientific progress.
A list of examples of modern trials that 
also fulfil the criteria of SMART studies is 
shown in table 2.
Table 2. Modern trials which fulfil the criteria for Spontaneous Medically Advantageous Research Trials (SMART) studies.
Project Title Promoting country/scientific association Started in
REstrictive versus LIbEral Fluid Therapy in Major Abdominal Surgery Australia 2014
The BALANCED Anesthesia Study
A prospective, randomized clinical trial of two levels of anaesthetic depth on 
patient outcome after major surgery
Australia 2014
Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery 
(RISCCS)
Canada 2014
Early Non-invasive Ventilation Outside the Intensive Care Unit Italy 2014
Volatile anesthetics to reduce mortality in cardiac surgery. A multicentre rand-
omized controlled study.
Italy 2012
International Prospective Observational Study of Mechanical Ventilation Dis-
continuation Practices. IOSwean.
Canadian Critical Care Trials Group 2012
Furthermore, due to the inherent nature 
of SMART research as previously defined, 
we believe that specific, additional insur-
ance and other bureaucratic requirements 
should be waived. The need for written in-
formed consent will vary according to the 
type of study.
In order to guarantee that the principles of 
Helsinki are respected, we suggest that some 
requirements for SMART trials be fulfilled.
Observational studies will be performed 
without specific ad hoc written consent and 
without the need for approval by the local 
ethical committee. At the time of submis-
sion of the study as a scientific article, peer 
reviewers will evaluate the study, and they 
may require further ethical information or 
evaluation by the local ethical committee 
when deemed necessary. This process will 
be appropriate for all types of observational 
studies, thus including retrospective stud-
ies, observational studies collecting normal-
ly discarded material (urine/feces) or blood, 
prospective observational studies collecting 
survey and questionnaire data, single center 
before-and-after studies.
Moreover, when an author wants to per-
form an interventional SMART study (in-
cluding multicenter cluster randomised 
controlled trials (RCTs), multicenter 
stepped wedge design studies, pilot change 
of practice studies, …), the study protocol 
might, for example, be required to:
Receive written support from at least 10 
independent physicians working in at least 
5 different nations in at least 2 different 
continents. These physicians could have 
experience in research activity (at least 20 
papers already published in indexed jour-
nals), and should obtain all data that they 
need to evaluate the work before giving 
their written approval.
Be uploaded on an international online 
database.
Offer all the patients the best available 
standard treatment as control therapy (as 
agreed by the above clinicians).
The need for a specific written consent for 
SMART interventional studies is not es-
tablished a priori. The authors of the study 
protocol will evaluate whether an ad hoc 
informed consent is needed for their study. 
The 10 independent physicians who will 
eventually approve the paper will evaluate 
the study protocol and confirm the pro-
posal or suggest changes to the study pro-
tocol concerning this aspect.
Finally, a Central Ethics Committee should 
confirm that the protocol is SMART. All 
the studies will be accessible online via a 
website, together with the written approv-
als (with signatures) by the 10 physicians. 
In this way, transparency towards medical 
colleagues and patients would be ensured. 
This procedure would be fully standard-
ized, in order to guarantee that SMART 
research by worthy researchers all over the 
world is not delayed.
In order to further ensure that this simpli-
fied procedure for SMART will not carry 
damage to patients, we also imagine a mul-
tiphase process.
Initially, this procedure would be imple-
mented and tested for a limited period of 
time. This first phase may last 3 years, and 
then an analysis of all SMART processes 
performed will be carried out, in order to 
identify their impact on patients, the ben-
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efits, and the potential critical issues which 
should be addressed. After this rational 
and scientific justification of SMART in-
terventions, the second phase would begin, 
that is to say, the SMART process will be-
come routine practice with no time limit.
SMART research is not only a new way of 
doing research: it is a new mind-set. For 
this reason, great efforts should be made 
to promote, spread and explain this ap-
proach all over the world. Politicians, pa-
tients, and associations of patients must all 
be protagonists. Scientists will be directly 
involved, as we will organize consensus 
conferences on SMART research to pro-
mote this concept and to address specific 
issues. Campaigns to promote SMART re-
search should be set up through the web. 
A preferential route for the presentation 
of SMART abstracts at congresses and 
the publication of SMART papers should 
be guaranteed. As the direct involvement 
of patients is crucial for success, SMART 
activities should be made public using lay 
media (televisions, newspapers, internet) 
and members of the public should be in-
volved in the development process.
The participation of patients should be 
further facilitated using technology and 
the patients’ preferred instruments. For 
example, the follow-up of studies could be 
performed by SMS, e-mail, or through ad 
hoc designed applications on Smartphones 
and tablets.
The potential of SMART research is sub-
stantial: it is therefore crucial that it be pro-
tected from financial issues that influence 
sponsored research and from the severe 
budget constraints caused by bureaucracy 
and redundant insurances.
SMART can lead the way of scientific re-
search. It is time to write a new Declara-
tion of Helsinki, to protect patients from 
not being involved in research, to widen 
the horizons of biomedical research, and to 
finally implement the transition to a learn-
ing health care system.
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